Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Fiche publication
Date publication
mars 2022
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr VERNEREY Dewi, Dr DERANGERE Valentin
Tous les auteurs :
Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, Vernerey D, Taieb J, Svrcek M,
Lien Pubmed
Résumé
Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in colon cancer (CC). We explored further the significance of Bd for risk stratification by evaluating survival of stage III CC patients included in the IDEA-France phase III trial.
Mots clés
colon cancer, prognostic, stage III colon cancer, tumor budding
Référence
Ann Oncol. 2022 Mar 16;: